6-[2-hydroxy-3-[methyl(pyridin-2-ylmethyl)amino]propoxy]-1H-quinolin-2-one | 128667-80-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-[2-hydroxy-3-[methyl(pyridin-2-ylmethyl)amino]propoxy]-1H-quinolin-2-one
• CAS: 128667-80-1
• 化学式: C₁₉H₂₁N₃O₃
• 分子量: 339.394
• InChiKey: VOQABFCESPSLIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  74.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-[(甲氨基)甲基]吡啶 、 6-(2,3-epoxypropoxy)-2(1H)-quinolinone 以 甲醇 为溶剂， 反应 3.0h， 生成 6-[2-hydroxy-3-[methyl(pyridin-2-ylmethyl)amino]propoxy]-1H-quinolin-2-one
  参考文献：
  名称：

  Novel positive inotropic agents: synthesis and biological activities of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinone derivatives

  摘要：

  A series of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinones has been synthesized and evaluated for positive inotropic activity on the canine heart. Some of these derivatives have a potent activity with none or negative chronotropic effect in isolated, blood-perfused dog heart preparations. They also display a high selectivity for positive inotropic effect over chronotropic and vasodilatory effects in anesthetized dogs. (+/-)-6-[2-Hydroxy-3-[(3-methoxybenzyl)amino]propoxy]-2(1H)-quinolinone (39) and (+/-)-6-[3-(3,4-dimethoxybenzyl)amino]-2-hydroxypropoxy]-2(1H)-quinolinone (40) were further investigated in conscious dogs. After iv administration, they did not affect heart rate or mean blood pressure at the dose producing a 50% increase in the peak of the first derivative of the left ventricular pressure. The compounds (39,OPC-18750, and 40,OPC-18790) are the most promising agents with desirable biological activities, and now are currently undergoing clinical evaluation.

  DOI：

  10.1021/jm00098a003

文献信息

• Cardiotonics
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0355583A2

  公开（公告）日：1990-02-28

  Agent for prophylaxis and treatment of heart diseases using a carbostyril derivative of formula: wherein R1 is H or CN, and R2 and R3 are each H, alkyl optionally substituted by OH, cycloalkyl, alkenyl, phenyl, phenylalkyl having optionally substituents of alkoxyalkoxy, halogen, alkoxy, N02, alkyl, CN, alkylthio or alkylsulfinyl on phenyl ring and having optionally OH-substituent on alkyl moiety, phenylsulfonylalkyl having optionally alkoxy substituent on phenyl ring, phenylthioalkyl, phenylsulfinylalkyl having optionally substituents of halogen or alkoxy on phenyl ring, phenoxyalkyl having optionally substituents of halogen or alkoxy on phenyl ring, pyridylalkyl having optionally substituents of halogen or alkoxy on pyridine ring, thienylalkyl, benzoylalkyl, anilinothiocarbonyl, benzoyl, pyridyl, phenylalkenyl, or group of -A-NR4R5 (R4 and R5, are each alkyl or phenyl having optionally substituents of halogen or alkoxy on phenyl ring, and A is alkylene which may be interrupted with 0), and a salt thereof, and novel carbostyril derivatives, and pharmaceutical composition for prophylaxis and treatment of heart diseases containing said novel carbostyril derivative.

  用于预防和治疗心脏病的制剂，使用式中的羧基吡啶衍生物： 其中 R1 是 H 或 CN，R2 和 R3 分别是 H、任选被 OH 取代的烷基、环烷基、烯基、苯基、苯基环上任选具有烷氧基、卤素、烷氧基、N02、烷基、CN、烷硫基或烷基亚磺酰基的苯基烷基以及烷基上任选具有 OH 取代基的苯基烷基、苯基环上有卤素或烷氧基取代基的苯磺酰烷基、苯硫酰烷基、苯基环上有卤素或烷氧基取代基的苯亚磺酰烷基、苯基环上有卤素或烷氧基取代基的苯氧基烷基、在吡啶环上可选择卤素或烷氧基取代基的吡啶烷基、噻吩烷基、苯甲酰烷基、苯甲硫羰基、苯甲酰基、吡啶基、苯基烯基或-A-NR4R5（R4 和 R5 均为在苯基环上可选择卤素或烷氧基取代基的烷基或苯基）基团、及其盐、新型卡波替林衍生物，以及含有上述新型卡波替林衍生物的预防和治疗心脏病的药物组合物。
• Carbostyril derivatives as phosphodiesterase inhibitors
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0647447A1

  公开（公告）日：1995-04-12

  A pharmaceutical preparation comprising at least one compound selected from the group consisting of carbostyril derivatives having the general formula: wherein R¹ is hydrogen or a lower alkyl group optionally having hydroxy group as a substituent; R² is a phenyl(lower alkyl) group optionally having 1 to 3 substituents selected from the group consisting of a lower alkoxy group and a halogen atom on the phenyl ring, pyridyl(lower alkyl) group, or a group of the formula -A-NR³R⁴ (wherein A is a lower alkylene group, R³ and R⁴ are the same or different and represent a lower alkyl group or phenyl group), and a salt thereof, which is useful as an agent for treating thrombosis, more particularly, as an agent for inhibiting platelet aggregation, an agent for platelet aggregate dissociation, an ameliorant of cerebral circulation and a phosphodiesterase inhibitor.

  一种药物制剂，包含至少一种选自具有通式的羧甲吡啶衍生物的化合物： 其中 R¹ 是氢或可选择具有羟基作为取代基的低级烷基；R² 是苯基（低级烷基）基团，可任选具有 1 至 3 个取代基，这些取代基可从苯基环上的低级烷氧基和卤原子、吡啶基（低级烷基）基团或式 -A-NR³R⁴ 的基团组成的组中选出（其中 A 是低级亚烷基、R³和R⁴相同或不同，代表低级烷基或苯基）及其盐，可用作治疗血栓的药物，特别是用作抑制血小板聚集的药物、血小板聚集解离剂、脑循环改善剂和磷酸二酯酶抑制剂。
• Carbostyril derivatives as anti-thrombotic agents
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0531548B1

  公开（公告）日：1995-09-27
• US5053514A
  申请人：——

  公开号：US5053514A

  公开（公告）日：1991-10-01
• US5198448A
  申请人：——

  公开号：US5198448A

  公开（公告）日：1993-03-30